The treatment paradigms for the management of rectal cancers continues to evolve with more data emerging on short course radiotherapy, total neoadjuvant therapy, and the development of non-operative management algorithms. Given the rapid evolution an understanding of the available data is crucial to the practitioner to provide high quality and cost effective care to patients. For anal cancers, a malignancy treated definitively with chemoradiation, advances in radiotherapy techniques has reduced significant toxicity in this patient cohort. An in depth understanding of radiotherapy simulation, treatment planning and treatment delivery for anorectal cancers will be provided that can be immediately incorporated into clinical practice.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, radiation physicists, nurses, radiation therapists, and radiation dosimetrists.
- Discuss the available literature to guide treatment decision in the management of lower GI malignancies.
- Develop techniques in simulation, treatment planning and treatment delivery to optimize radiotherapy delivery and minimize associated toxicities.
Daniel Chang, MD is employed by Stanford, receives compensation/remuneration/funding from Varian Inc., has ownership/investments in Viewray.
Manisha Palta, MD is employed by Duke University, receives compensation/remuneration/funding from Merck, UptoDate and holds leadership positions at ASTRO and ASCO.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.